Literature DB >> 2366078

Primary central nervous system lymphomas: natural history and response to radiation therapy in 55 patients with acquired immunodeficiency syndrome.

J E Baumgartner1, J R Rachlin, J H Beckstead, T C Meeker, R M Levy, W M Wara, M L Rosenblum.   

Abstract

The incidence of primary central nervous system (CNS) lymphoma has increased rapidly in patients with acquired immunodeficiency syndrome (AIDS) and is predicted to exceed 1800 cases annually by 1991. To characterize the natural history and response to radiation therapy (RT) of these lesions, the authors have reviewed the clinical histories of 55 AIDS patients with biopsy-proven primary CNS lymphomas. The tumors responded both clinically and radiologically to whole-brain RT consisting of 4000 rad in 267-rad fractions over 3 weeks or an equivalent neuroret dose. The mean duration of survival from the appearance of symptoms consistent with the mass lesion was significantly greater in patients who received RT than in those who did not (42 vs. 134 days, p less than 0.5; median 27 vs. 119 days). Autopsy findings showed that patients who did not receive RT died from tumor progression, whereas those who completed RT died of opportunistic infections. Patients with AIDS who are suspected of having primary CNS lymphoma should therefore immediately undergo biopsy and, if the diagnosis is confirmed, whole-brain RT. With early diagnosis and treatment, these tumors respond to, and patients benefit from, RT. Survival of such patients may in future be prolonged by more effective treatments for systemic opportunistic infections.

Entities:  

Mesh:

Year:  1990        PMID: 2366078     DOI: 10.3171/jns.1990.73.2.0206

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  32 in total

Review 1.  HIV-associated lymphomas.

Authors:  D J Straus
Journal:  Curr Oncol Rep       Date:  2001-05       Impact factor: 5.075

2.  Cancer and HIV infection.

Authors:  L Hughes-Davies; M Spittle
Journal:  BMJ       Date:  1991-03-23

3.  Lesion size determines accuracy of thallium-201 brain single-photon emission tomography in differentiating between intracranial malignancy and infection in AIDS patients.

Authors:  Robert J Young; Munir V Ghesani; Nolan J Kagetsu; Andrew J Derogatis
Journal:  AJNR Am J Neuroradiol       Date:  2005-09       Impact factor: 3.825

4.  Metastatic cerebral lymphoma.

Authors:  L Hughes-Davies; M Spittle; M J Harrison; S B Lucas; R F Miller
Journal:  Genitourin Med       Date:  1991-08

5.  Zidovudine-based lytic-inducing chemotherapy for Epstein-Barr virus-related lymphomas.

Authors:  Ulas Darda Bayraktar; Luis A Diaz; Brittany Ashlock; Ngoc Toomey; Lisa Cabral; Soley Bayraktar; Denise Pereira; Dirk P Dittmer; Juan Carlos Ramos
Journal:  Leuk Lymphoma       Date:  2013-08-28

Review 6.  Central nervous system infection during immunosuppression.

Authors:  Joseph R Zunt
Journal:  Neurol Clin       Date:  2002-02       Impact factor: 3.806

7.  Risk of HIV dementia and opportunistic brain disease in AIDS and zidovudine therapy.

Authors:  T Baldeweg; J Catalan; B G Gazzard
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-07       Impact factor: 10.154

8.  Malignant lymphomas in HIV-seropositive patients. Frequency, features, and prognosis. Report on 31 cases.

Authors:  D Schürmann; D Dienemann; G Jautzke; J Cervos-Navarro; A Langford; H Stein; H D Pohle; B Ruf
Journal:  Klin Wochenschr       Date:  1991-10-02

9.  Primary central nervous system lymphoma in Japan--a retrospective, co-operative study by CNS-Lymphoma Study Group in Japan.

Authors:  T Hayakawa; K Takakura; H Abe; T Yoshimoto; R Tanaka; K Sugita; H Kikuchi; T Uozumi; T Hori; H Fukui
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

Review 10.  The role of macrophages in the development and progression of AIDS-related non-Hodgkin lymphoma.

Authors:  Leanne C Huysentruyt; Michael S McGrath
Journal:  J Leukoc Biol       Date:  2009-12-30       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.